TOKYO & BOSTON--(BUSINESS WIRE)--Bain Capital, a leading global private investment firm, today announced it has signed a definitive agreement to acquire Mitsubishi Tanabe Pharma Corporation ...

Following rumblings of a private equity bidding war late last year, Bain Capital has emer | Bain Capital is laying out 510 ...

is acquiring Mitsubishi Tanabe Pharma Corporation in a multi-billion dollar deal that brings a portfolio of products marketed globally along with a drug pipeline spanning several key therapeutic ...

Independent company plans significant investment in innovation, both internal product development ... a definitive agreement to acquire Mitsubishi Tanabe Pharma Corporation (“Tanabe Pharma ...

both internal product development and external licensing and acquisitions, supported by Bain Capital investment Founded in 1678, Tanabe Pharma is headquartered in Doshomachi, Osaka, the birthplace ...

Bain Capital has agreed to acquire Mitsubishi Chemical Group's pharmaceutical ... by Bain Capital, Tanabe plans to make significant investments in both internal product development and external ...

Mitsubishi Chemical Group, Japan’s largest chemical company, announced Feb. 7 that it will sell its pharmaceutical subsidiary, Mitsubishi Tanabe Pharma ... One of its key products is Radicava ...

To report suspected adverse reactions or product complaints, contact Mitsubishi Tanabe Pharma America, Inc., at 1-888-292-0058. You may also report suspected adverse reactions to the FDA at 1-800 ...

Mitsubishi Tanabe Pharma (MTPC), which engages in the manufacturing and sales of pharmaceutical products, to K.K. BCJ-94, a special purpose company indirectly owned by Bain Capital for around 510 ...